Acetylsalicylic acid disrupts SARS-CoV-2 spike protein glycosylation and selectively impairs binding to ACE2
Hallo…..INTERESTING ITALIAN PREPRINT!
Acetylsalicylic acid (aspirin), dose-dependently, directly impairs the SARS-CoV-2 spike protein’s ability to bind ACE2 by modifying its glycosylation at key sites (N61 and S325).
This prevents the spike from effectively engaging its receptor, dramatically reducing lung injury, inflammation, and fibrosis in humanized ACE2 mice.
Mutating those same glycosylation sites replicates aspirin’s protective effect.
These findings reveal a novel antiviral mechanism for aspirin and provide strong molecular evidence for repurposing this inexpensive, widely available drug to limit progression to severe COVID-19.
ASPIRIN keeps on giving.......maybe WHO needs to update their guidlines!
Eagerly awaiting peer-review with doses used!
frontiersin.org/journals/immun
Hallo…..INTERESTING ITALIAN PREPRINT!
Acetylsalicylic acid (aspirin), dose-dependently, directly impairs the SARS-CoV-2 spike protein’s ability to bind ACE2 by modifying its glycosylation at key sites (N61 and S325).
This prevents the spike from effectively engaging its receptor, dramatically reducing lung injury, inflammation, and fibrosis in humanized ACE2 mice.
Mutating those same glycosylation sites replicates aspirin’s protective effect.
These findings reveal a novel antiviral mechanism for aspirin and provide strong molecular evidence for repurposing this inexpensive, widely available drug to limit progression to severe COVID-19.
ASPIRIN keeps on giving.......maybe WHO needs to update their guidlines!
Eagerly awaiting peer-review with doses used!
frontiersin.org/journals/immun